Connect Biopharma Holdings Limited - Ordinary Shares (CNTB)
CNTB moved a median of 0.00% 30 minutes after news, and -1.64% by the close. How CNTB actually reacts to news — the realized, point-in-time move the market made, measured across 173 labeled events over the last three years with zero look-ahead.
CNTB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.18% | 30% | 164 |
| 30-min | 0.00% | 48% | 170 |
| 60-min | 0.00% | 49% | 171 |
| to close | -1.64% | 36% | 173 |
| Middle 50% of CNTB reactions | -2.49% to +2.08% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 173 |
Half of all Connect Biopharma Holdings Limited - Ordinary Shares news events land between -2.49% and +2.08% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CNTB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 26 | -0.70% | 35% | +1.16% |
| Rating reiterations | 22 | -0.11% | 46% | -3.27% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how CNTB ranks against every other measured name →
That’s how CNTB usually reacts — get an email when it moves on news →Email me when CNTB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CNTB's baseline. Nothing else.
Recent CNTB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation | Press release | GlobeNewswire | -12.23% | -41.49% | |
| Form 8-K Connect Biopharma Holdin For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -12.23% | -41.49% | |
| Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation | Press release | GlobeNewswire | -4.68% | -8.59% | |
| Form 8-K Connect Biopharma Holdin For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -4.68% | -8.59% | |
| Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | -2.98% | -8.46% | |
| Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +2.15% | +9.01% | |
| Form 10-Q Connect Biopharma Holdin For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.15% | +9.01% | |
| Form 8-K Connect Biopharma Holdin For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +2.15% | +9.01% | |
| Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma | Press release | GlobeNewswire | +1.24% | +2.97% | |
| Form EFFECT Connect Biopharma Holdin | SEC filing · Form EFFECT | SEC EDGAR | -0.43% | -8.12% | |
| Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight | Press release | PR Newswire | -1.71% | -6.41% | |
| Form F-3 Connect Biopharma Holdin | SEC filing · Form F-3 | SEC EDGAR | +0.41% | -1.65% | |
| Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | +12.61% | |
| Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference | Press release | GlobeNewswire | +0.00% | -5.41% | |
| Form 10-Q Connect Biopharma Holdin For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +12.61% | |
| Form 8-K Connect Biopharma Holdin For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +12.61% | |
| Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis | Press release | GlobeNewswire | +0.58% | -3.08% | |
| Form 8-K Connect Biopharma Holdin For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | +0.58% | -3.08% | |
| Ickey Woods Kicks Off "Score 6 for 24" Fundraising Campaign to Expand Asthma Testing for Children Nationwide | Press release | PR Newswire | -0.43% | +0.71% | |
| Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.63% | +2.26% | |
| Form 10-K Connect Biopharma Holdin For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.63% | +2.26% | |
| Form 8-K Connect Biopharma Holdin For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -2.63% | +2.26% | |
| Signadori Bio appoints Dr. Selwyn Ho, MB BS as Chief Executive Officer to lead company into next stage of growth | Press release | Business Wire | +3.78% | -5.75% | |
| Connect Biopharma Announces $20.2 Million Private Placement Financing | Press release | GlobeNewswire | -11.88% | -19.89% | |
| Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD | Press release | GlobeNewswire | -11.88% | -19.89% | |
| Form 8-K Connect Biopharma Holdin For: Mar 29 | SEC filing · Form 8-K | SEC EDGAR | -11.88% | -19.89% | |
| Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study | Press release | GlobeNewswire | -11.88% | -19.89% | |
| Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight | Press release | PR Newswire | — | -1.46% | |
| Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting | Press release | GlobeNewswire | +5.76% | +3.72% | |
| Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight | Press release | PR Newswire | +1.22% | +0.41% | |
| Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference | Press release | GlobeNewswire | +0.00% | +1.22% | |
| Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | -8.08% | -2.36% | |
| House Dust Mite Disease Market to Exhibit Substantial Growth at a CAGR of 3.5% During the Forecast Period (2025-2034) | DelveInsight | Press release | PR Newswire | +0.00% | +1.37% | |
| Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 | Press release | GlobeNewswire | -3.18% | -3.64% | |
| Form 8-K Connect Biopharma Holdin For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +9.20% | |
| Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | -7.44% | -5.83% | |
| Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV | Press release | ACCESS Newswire | +8.70% | +31.68% | |
| Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +5.37% | +8.05% | |
| Form 10-Q Connect Biopharma Holdin For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.37% | +8.05% | |
| Form 8-K Connect Biopharma Holdin For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +5.37% | +8.05% | |
| Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 | Press release | ACCESS Newswire | -0.63% | -1.27% | |
| Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025 | Press release | GlobeNewswire | -4.72% | -16.11% | |
| Form 8-K Connect Biopharma Holdin For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.01% | |
| Form EFFECT Connect Biopharma Holdin | SEC filing · Form EFFECT | SEC EDGAR | +4.38% | +0.00% | |
| Form POS AM Connect Biopharma Holdin | SEC filing · Form POS | SEC EDGAR | -0.68% | -7.39% | |
| Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight | Press release | PR Newswire | — | -1.12% | |
| Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025 | Press release | GlobeNewswire | -0.52% | -6.81% | |
| Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq | Press release | GlobeNewswire | -9.79% | -9.54% | |
| Connect Biopharma to Present at Two Upcoming Investor Conferences in September | Press release | GlobeNewswire | +0.39% | -0.56% | |
| Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide | Press release | GlobeNewswire | -3.31% | -8.51% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CNTB section they belong to.
Where else CNTB is measured.
CNTB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Connect Biopharma Holdings Limited - Ordinary Shares's median reaction calculated?
Every labeled CNTB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 173 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of CNTB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CNTB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.